Regulation and welfare: Evidence from paragraph IV generic entry in the pharmaceutical industry
Document Type
Article
Publication Title
Rand Journal of Economics
Abstract
We thank Tamer Abdelgawad, Serguey Braguinsky, Iain Cockburn, Marty Gaynor, David Greenstreet, Bart Hamilton, Lowell Taylor, Jerry Thursby, Kenneth Train, Scott Stern, Dietmar Harhoff, Carolin Haeussler, Murray Aitken, Kensuke Kubo, Vineet Kumar, Jian Ni, and Ellerie Weber, as well as seminar participants at Emory, Cornell, Carnegie Mellon, IIM Bangalore, IIM Ahmedabad, Passau, Charles River Associates, Precision Health Economics, and the NBER Summer Institute (Cambridge, 2011) for valuable comments and discussions. We thank Bhaven Sampat for helpful comments and for sharing patent data. We are grateful to Judith Chevalier and two anonymous referees for detailed comments and suggestions that significantly improved an earlier draft. We thank Susan Jack, Margaret Warner, and Robert Anderson for guidance in using the National Health Interview Survey, and we thank Antara Dutta for sharing her code with us as well as for extensive discussions. Programming assistance by Avadhoot Jathar, Nachiket Sahoo, Anubrata Banerjee, and Trupti Natu is appreciated. We are grateful for the time Dr. Terry Simon and Dr. Ronald Severtis spent explaining to us the treatment of hypertension. We also thank Murray Aitken and IMS Health Incorporated for their generous support and access to their data. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IMS Health Incorporated or any of its affiliated or subsidiary entities. The statements, findings, conclusions, views, and opinions contained and expressed in this article are based in part on data obtained under license from the following IMS Health Incorporated or affiliate information service(s): IMS Midasâ„¢, IMS Lifecycleâ„¢, IMS National Disease and Therapeutic Indexâ„¢, IMS National Prescription Auditâ„¢, January 2000 to December 2008, IMS Health Incorporated or its affiliates. All Rights Reserved. Higgins acknowledges funding from The Imlay Professorship and Pfizer, Inc. Chatterjee and Branstetter acknowledge funding from NSF SCISIP grant no. #0830233 and from the Young Faculty Research Chair at IIM Bangalore. Authors are listed alphabetically and the usual disclaimers apply.
Publication Date
11-11-2016
Publisher
Wiley-Blackwell Publishing, Inc.
Volume
Vol.47
Issue
Iss.4
Recommended Citation
Branstetter, Lee; Chatterjee, Chirantan; and Higgins, Matthew J, "Regulation and welfare: Evidence from paragraph IV generic entry in the pharmaceutical industry" (2016). Faculty Publications. 392.
https://research.iimb.ac.in/fac_pubs/392